An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART)

AIDS Behav. 2018 Mar;22(3):939-947. doi: 10.1007/s10461-017-1759-9.

Abstract

Relying on the most frequently reported barriers to adherence and convenient definitions of non-adherence may lead to less valid results. We used a dominance analysis (a regression-based approach) to identify the most important barriers to adherence based on effect size using data collected through an online survey. The survey included the Adherence Barrier Questionnaire, self-reported non-adherence defined as a 4-day treatment interruption, and HIV clinical outcomes. The sample (N = 1217) was largely male, gay identified, and White. Nearly 1 in 3 participants reported "simply forgot" as a barrier; however, in a dominance analysis, it yielded a small effect size it its association with a 4-day treatment interruption. Further, dominance analyses stratified by race/ethnicity and age suggested that not all barriers impact all groups equally. The most frequently reported barriers to adherence were not the most important, and interventions should focus on barriers more strongly linked to clinical outcomes.

Keywords: Adherence; Adherence barriers; Antiretroviral therapy; Dominance analysis; Relative importance.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Attitude to Health*
  • Black or African American / psychology
  • Black or African American / statistics & numerical data
  • HIV Infections / drug therapy*
  • HIV Infections / psychology*
  • Hispanic or Latino / psychology
  • Hispanic or Latino / statistics & numerical data
  • Homosexuality, Male* / psychology
  • Homosexuality, Male* / statistics & numerical data
  • Humans
  • Male
  • Medication Adherence / psychology*
  • Middle Aged
  • Pain Management
  • Self Report
  • Social Support
  • Stress, Psychological
  • Surveys and Questionnaires
  • White People / psychology

Substances

  • Anti-HIV Agents